Third in line: Ed­i­tas says it may part­ner up on com­mer­cial­iza­tion of sick­le cell gene ther­a­py

Ed­i­tas Med­i­cine con­tin­ues to churn along in a sol­id third place in the race against blue­bird bio, and part­ners Ver­tex and CRISPR to com­mer­cial­ize the first, po­ten­tial­ly life-chang­ing gene ther­a­py to treat sick­le cell dis­ease.

The Cam­bridge, MA-based biotech said Wednes­day in its quar­ter­ly earn­ings call that it ex­pects to dose about 20 sick­le cell pa­tients and re­lease more da­ta by year’s end. The com­pa­ny’s top brass al­so said it may end up co-com­mer­cial­iz­ing the po­ten­tial­ly mil­lion-dol­lar gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER